bevacizumab + interferon alfa-2a + vinblastine

This combination comprises three drugs: **bevacizumab** (a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A, or VEGF-A), **interferon alfa-2a** (a recombinant cytokine that modulates immune response and has antiproliferative and antiangiogenic effects), and **vinblastine** (a vinca alkaloid antineoplastic agent that inhibits microtubule formation, causing mitotic arrest and apoptosis). Bevacizumab blocks angiogenesis by sequestering VEGF-A, thereby inhibiting new blood vessel formation essential for tumor growth[1][3][5]. Interferon alfa-2a stimulates immune functions and also hinders angiogenesis, supporting antitumor activity[2][3]. Vinblastine disrupts cell division by arresting microtubule assembly, leading to tumor cell death. The combination aims to leverage synergistic antitumor effects via inhibition of blood vessel growth (bevacizumab), stimulation of immune-mediated tumor suppression (interferon alfa-2a), and direct cytotoxic action on dividing cells (vinblastine). This combination has been studied mainly in the context of clinical trials for **metastatic renal cell carcinoma** (mRCC), though the standard approved combination is bevacizumab plus interferon alfa-2a, without vinblastine[1][3][5].